Articles from AimedBio

AimedBio today announced that the first patient has been dosed in a Phase I study of BI 4060107, an investigational antibody-drug conjugate (ADC) discovered by AimedBio and now being developed by Boehringer Ingelheim under the companies’ global collaboration and licensing agreement. The first-in-human study (NCT07827144) is evaluating different doses of BI 4060107 in people with advanced solid tumors, with a focus on how well the treatment is tolerated.